(43)For the active substances fenpyroximate, fluazinam, flutolanil, proquinazid, pyrethrins and pyrimethanil, on 4 November 2021, 17 June 2021, 12 July 2019, 12 April 2024, 28 August 2023 and 16 December 2019, respectively, additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605note, was requested by the Authority in consultation with the Member States pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012. The additional information for fenpyroximate, fluazinam, flutolanil, proquinazid and pyrimethanil was submitted by the applicants within the deadline given, and for pyrethrins the submission is pending. The rapporteur Member States submitted the revised draft renewal assessment reports for fenpyroximate, fluazinam, flutolanil, proquinazid, pyrimethanil and flurochloridone to the Authority and the public consultations on them finished on 24 November 2024, 28 September 2024, 24 June 2022, 13 June 2025 and 12 December 2022, respectively. However, additional time is needed for the Authority to complete the evaluation and to finalise its conclusions for fenpyroximate, fluazinam and proquinazid, as well as for the Commission to adopt the ensuing risk management decision.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.